Chief Executive's Quote

We intend to move forward with our human-health focus, leaning towards mental health parity through developing potential treatments for schizophrenia, dementia, and depression.

In terms of COVID-19, I see us addressing this pandemic through a variety of tools, be it traditional Chinese medicines, FDA-approved chemical drugs, or regional-dependent health supplements.

As we forge ahead, we want to always meet these important health issues head on and with an efficient development process. Our goal is to bypass, when it is scientifically sound to do so, the sometimes decade-long delay or billion dollar cost chasm to develop new therapies.

Dr. Coyle Named Chief Scientific Advisor

Sep 20, 2022

Media - verywellmind

SyneuRx is currently conducting clinical development of two COVID-19 treatments— Pentarlandir® in oral capsule form and Airnecflu® in an inhaled form. Pentarlandir® completed US Phase 2 clinical trial in June 2022 (click here for trial information). The Phase 3 study is expected to be launched in late 2022 as a global multi-center clinical trial. First-in-human study for Airnecflu® is expected to launch in the second half of 2022.
Pentarlandir for COVID-19 (Oral Antiviral)
Phase 2
Airneclfu for COVID-19 (Inhaler)
Phase 1
NaBen for Adult Schizophrenia
Phase 2/3
ClozaBen for Refractory Schizophrenia
Phase 2/3
NaBen for Adolescent Schizophrenia
Phase 2/3
NaBen for Early Dementia
Phase 2/3
Tannquilynne for Dementia & Psychosis
Phase 2
Synapsinae for Depression and Suicidality
Phase 3
Synxyrin for Treatment Resistant Depression
Phase 2



SNB01 COVID-19 Antiviral

Enrollment Complete
Learn More
snd12a-300x300 copy



SND13 Adult Schizophrenia

Learn More
SND13a-300x300 copy


Refractory Schizophrenia

SND12 Refractory Schizophrenia

Learn More
SND13-291x300 copy


Adolescent Schizophrenia

SND11 Adolescent Schizophrenia

Learn More